Latest Breaking News On - Cisplatin induced ototoxicity - Page 1 : comparemela.com

Sensorion Publishes Results of Combined Shareholders General Meeting Resolutions

Regulatory News: Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss.

Institut pasteurRegulatory newsCombined general meetingGeneral meetingCisplatin induced ototoxicityCochlear limitedSudden sensorineural hearing loss

Sensorion Announces its Participation in Upcoming Investor Conferences in June 2024

Regulatory News: Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss.

France generalUnited statesNew yorkInstitut pasteurGoldman sachsRegulatory newsJefferies global healthcare conferenceAnnual global healthcare conferenceEuropean healthcare summit lyonCisplatin induced ototoxicityCochlear limitedSudden sensorineural hearing loss

Sensorion Provides Preliminary Documents for the Combined Shareholders General Meeting of May 29, 2024

Sensorion Provides Preliminary Documents for the Combined Shareholders General Meeting of May 29, 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

France generalSquare louvoisInstitut pasteurNicolas entzRegulatory newsCombined general meetingFrench commercial codeGeneral meetingAnnual general meetingCombined shareholder general meetingCisplatin induced ototoxicityCochlear limitedSudden sensorineural hearing lossInvestor relationsCommunications associateCarsten stork

Sensorion Provides Preliminary Documents for the Combined Shareholders General Meeting of May 29, 2024 | Region

MONTPELLIER, France (BUSINESS WIRE) May 7, 2024

France generalNicolas entzInstitut pasteurSquare louvoisCombined general meetingFrench commercial codeGeneral meetingAnnual general meetingCombined shareholder general meetingCisplatin induced ototoxicityCochlear limitedSudden sensorineural hearing lossInvestor relationsBusiness wire

Sensorion Announces its Participation in the American Society of Cell and Gene Therapy (ASGCT) Annual Meeting

Regulatory News: Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss.

United statesRafik boudraInstitut pasteurGroup leader technologyPreclinical developmentAmerican society of cellRegulatory newsAnnual american societyGene therapy meetingExhibit hallAutosomal recessive non syndromic deafnessAdeno associated vector based gene therapyCisplatin induced ototoxicityCochlear limitedSudden sensorineural hearing loss